Literature DB >> 11781689

Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families.

R B Barkardottir1, L Sarantaus, A Arason, P Vehmanen, P O Bendahl, T Kainu, K Syrjäkoski, R Krahe, P Huusko, S Pyrhönen, K Holli, O P Kallioniemi, V Egilsson, J Kere, H Nevanlinna.   

Abstract

The 999del5 mutation is the single, strong BRCA2 founder mutation in Iceland and the most common BRCA1/2 founder mutation in Finland. To evaluate the origin and time since spreading of the 999del5 mutation in Iceland and in Finland, we constructed haplotypes with polymorphic markers within and flanking the BRCA2 gene in a set of 18 Icelandic and 10 Finnish 999del5 breast cancer families. All Icelandic families analysed shared a common core haplotype of about 1.7 cM. The common ancestors for the Icelandic families studied were estimated to trace back to 340-1000 years, not excluding the possibility that the mutation was brought to Iceland during the settlement of the country. Analysis of the Finnish families revealed two distinct haplotypes. A rare one, found in three families in the old settlement region in southwestern Finland, shared a four-marker (0.5 cM) core haplotype with the Icelandic 999del5 haplotype. A distinct approximately 6 cM haplotype was shared by seven 999del5 Finnish families estimated to have a common ancestry 140-300 years ago. These families cluster in two geographical regions in Finland, in the very same area as those with the rare haplotype and also in the most eastern, late settlement region of Finland. The results may indicate a common ancient origin for the 999del5 mutation in Iceland and in Finland, but distinct mutational events cannot be ruled out. The surprising finding of the same mutation in two completely different haplotypes in a sparsely populated area in Finland may suggest gene conversion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781689     DOI: 10.1038/sj.ejhg.5200717

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  12 in total

1.  A populationwide coalescent analysis of Icelandic matrilineal and patrilineal genealogies: evidence for a faster evolutionary rate of mtDNA lineages than Y chromosomes.

Authors:  Agnar Helgason; Birgir Hrafnkelsson; Jeffrey R Gulcher; Ryk Ward; Kári Stefánsson
Journal:  Am J Hum Genet       Date:  2003-04-29       Impact factor: 11.025

2.  Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.

Authors:  Hélène Vézina; Francine Durocher; Martine Dumont; Louis Houde; Csilla Szabo; Martine Tranchant; Jocelyne Chiquette; Marie Plante; Rachel Laframboise; Jean Lépine; Heli Nevanlinna; Dominique Stoppa-Lyonnet; David Goldgar; Peter Bridge; Jacques Simard
Journal:  Hum Genet       Date:  2005-05-10       Impact factor: 4.132

3.  The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews.

Authors:  Lluís Quintana-Murci; Inbar Gal; Tangiz Bakhan; Hélène Quach; S Hamid Sayar; Ronit Shiri-Sverdlov; Ruth Gershoni Baruch; Ken McElreavey; Efrat Dagan; Steven Narod; Eitan Friedman
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

4.  The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.

Authors:  Inbar Gal; Ruth Gershoni Baruch; Daniel Haber; Efrat Dagan; Shlomit Eisenberg-Barzilai; Jamal Zidan; Eitan Friedman
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

5.  A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome.

Authors:  M Clendenning; L Senter; H Hampel; K Lagerstedt Robinson; S Sun; D Buchanan; M D Walsh; M Nilbert; J Green; J Potter; A Lindblom; A de la Chapelle
Journal:  J Med Genet       Date:  2008-01-04       Impact factor: 6.318

6.  BRCA2 mutations in 154 finnish male breast cancer patients.

Authors:  Kirsi Syrjäkoski; Tuula Kuukasjärvi; Kati Waltering; Karin Haraldsson; Anssi Auvinen; Ake Borg; Tommi Kainu; Olli-P Kallioniemi; Pasi A Koivisto
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

7.  Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome.

Authors:  Ingrid P Ewald; Patrícia Izetti; Fernando R Vargas; Miguel Am Moreira; Aline S Moreira; Carlos A Moreira-Filho; Danielle R Cunha; Sara Hamaguchi; Suzi A Camey; Aishameriane Schmidt; Maira Caleffi; Patrícia Koehler-Santos; Roberto Giugliani; Patricia Ashton-Prolla
Journal:  Hered Cancer Clin Pract       Date:  2011-12-20       Impact factor: 2.857

8.  Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Authors:  Vivek L Patel; Evan L Busch; Tara M Friebel; Angel Cronin; Goska Leslie; Lesley McGuffog; Julian Adlard; Simona Agata; Bjarni A Agnarsson; Munaza Ahmed; Kristiina Aittomäki; Elisa Alducci; Irene L Andrulis; Adalgeir Arason; Norbert Arnold; Grazia Artioli; Brita Arver; Bernd Auber; Jacopo Azzollini; Judith Balmaña; Rosa B Barkardottir; Daniel R Barnes; Alicia Barroso; Daniel Barrowdale; Muriel Belotti; Javier Benitez; Birgitte Bertelsen; Marinus J Blok; Istvan Bodrogi; Valérie Bonadona; Bernardo Bonanni; Davide Bondavalli; Susanne E Boonen; Julika Borde; Ake Borg; Angela R Bradbury; Angela Brady; Carole Brewer; Joan Brunet; Bruno Buecher; Saundra S Buys; Santiago Cabezas-Camarero; Trinidad Caldés; Almuth Caliebe; Maria A Caligo; Mariarosaria Calvello; Ian G Campbell; Ileana Carnevali; Estela Carrasco; Tsun L Chan; Annie T W Chu; Wendy K Chung; Kathleen B M Claes; Gemo Study Collaborators; Embrace Collaborators; Jackie Cook; Laura Cortesi; Fergus J Couch; Mary B Daly; Giuseppe Damante; Esther Darder; Rosemarie Davidson; Miguel de la Hoya; Lara Della Puppa; Joe Dennis; Orland Díez; Yuan Chun Ding; Nina Ditsch; Susan M Domchek; Alan Donaldson; Bernd Dworniczak; Douglas F Easton; Diana M Eccles; Rosalind A Eeles; Hans Ehrencrona; Bent Ejlertsen; Christoph Engel; D Gareth Evans; Laurence Faivre; Ulrike Faust; Lídia Feliubadaló; Lenka Foretova; Florentia Fostira; George Fountzilas; Debra Frost; Vanesa García-Barberán; Pilar Garre; Marion Gauthier-Villars; Lajos Géczi; Andrea Gehrig; Anne-Marie Gerdes; Paul Gesta; Giuseppe Giannini; Gord Glendon; Andrew K Godwin; David E Goldgar; Mark H Greene; Angelica M Gutierrez-Barrera; Eric Hahnen; Ute Hamann; Jan Hauke; Natalie Herold; Frans B L Hogervorst; Ellen Honisch; John L Hopper; Peter J Hulick; KConFab Investigators; Hebon Investigators; Louise Izatt; Agnes Jager; Paul James; Ramunas Janavicius; Uffe Birk Jensen; Thomas Dyrso Jensen; Oskar Th Johannsson; Esther M John; Vijai Joseph; Eunyoung Kang; Karin Kast; Johanna I Kiiski; Sung-Won Kim; Zisun Kim; Kwang-Pil Ko; Irene Konstantopoulou; Gero Kramer; Lotte Krogh; Torben A Kruse; Ava Kwong; Mirjam Larsen; Christine Lasset; Charlotte Lautrup; Conxi Lazaro; Jihyoun Lee; Jong Won Lee; Min Hyuk Lee; Johannes Lemke; Fabienne Lesueur; Annelie Liljegren; Annika Lindblom; Patricia Llovet; Adria Lopez-Fernández; Irene Lopez-Perolio; Victor Lorca; Jennifer T Loud; Edmond S K Ma; Phuong L Mai; Siranoush Manoukian; Veronique Mari; Lynn Martin; Laura Matricardi; Noura Mebirouk; Veronica Medici; Hanne E J Meijers-Heijboer; Alfons Meindl; Arjen R Mensenkamp; Clare Miller; Denise Molina Gomes; Marco Montagna; Thea M Mooij; Lidia Moserle; Emmanuelle Mouret-Fourme; Anna Marie Mulligan; Katherine L Nathanson; Marie Navratilova; Heli Nevanlinna; Dieter Niederacher; Finn C Cilius Nielsen; Liene Nikitina-Zake; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Kai-Ren Ong; Ana Osorio; Claus-Eric Ott; Domenico Palli; Sue K Park; Michael T Parsons; Inge Sokilde Pedersen; Bernard Peissel; Ana Peixoto; Pedro Pérez-Segura; Paolo Peterlongo; Annabeth Høgh Petersen; Mary E Porteous; Miguel Angel Pujana; Paolo Radice; Juliane Ramser; Johanna Rantala; Muhammad U Rashid; Kerstin Rhiem; Piera Rizzolo; Mark E Robson; Matti A Rookus; Caroline M Rossing; Kathryn J Ruddy; Catarina Santos; Claire Saule; Rosa Scarpitta; Rita K Schmutzler; Hélène Schuster; Leigha Senter; Caroline M Seynaeve; Payal D Shah; Priyanka Sharma; Vivian Y Shin; Valentina Silvestri; Jacques Simard; Christian F Singer; Anne-Bine Skytte; Katie Snape; Angela R Solano; Penny Soucy; Melissa C Southey; Amanda B Spurdle; Linda Steele; Doris Steinemann; Dominique Stoppa-Lyonnet; Agostina Stradella; Lone Sunde; Christian Sutter; Yen Y Tan; Manuel R Teixeira; Soo Hwang Teo; Mads Thomassen; Maria Grazia Tibiletti; Marc Tischkowitz; Silvia Tognazzo; Amanda E Toland; Stefania Tommasi; Diana Torres; Angela Toss; Alison H Trainer; Nadine Tung; Christi J van Asperen; Frederieke H van der Baan; Lizet E van der Kolk; Rob B van der Luijt; Liselotte P van Hest; Liliana Varesco; Raymonda Varon-Mateeva; Alessandra Viel; Jeroen Vierstraete; Roberta Villa; Anna von Wachenfeldt; Philipp Wagner; Shan Wang-Gohrke; Barbara Wappenschmidt; Jeffrey N Weitzel; Greet Wieme; Siddhartha Yadav; Drakoulis Yannoukakos; Sook-Yee Yoon; Cristina Zanzottera; Kristin K Zorn; Anthony V D'Amico; Matthew L Freedman; Mark M Pomerantz; Georgia Chenevix-Trench; Antonis C Antoniou; Susan L Neuhausen; Laura Ottini; Henriette Roed Nielsen; Timothy R Rebbeck
Journal:  Cancer Res       Date:  2019-11-13       Impact factor: 13.312

9.  Evidence against PALB2 involvement in Icelandic breast cancer susceptibility.

Authors:  Haukur Gunnarsson; Adalgeir Arason; Elizabeth M Gillanders; Bjarni A Agnarsson; Gudrun Johannesdottir; Oskar Th Johannsson; Rosa B Barkardottir
Journal:  J Negat Results Biomed       Date:  2008-07-17

10.  A novel mutation in the TG gene (G2322S) causing congenital hypothyroidism in a Sudanese family: a case report.

Authors:  Y Watanabe; E Sharwood; B Goodwin; M K Creech; H Y Hassan; M G Netea; M Jaeger; A Dumitrescu; S Refetoff; T Huynh; R E Weiss
Journal:  BMC Med Genet       Date:  2018-05-02       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.